PremiumThe FlyMerck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says Biotech Alert: Searches spiking for these stocks today Halozyme price target raised to $60 from $57 at Wells Fargo PremiumCompany AnnouncementsHalozyme Therapeutics Achieves Record Revenue in 2024 Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme Halozyme reports Q4 EPS $1.06, consensus $1.16 PremiumCompany AnnouncementsHalozyme Board Member Connie Matsui Steps Down Halozyme’s Strategic Advancements and Market Potential Justify Buy Rating Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics 
